Author: Aurenar

Aurenar Closes Oversubscribed $5.7M Seed Round Led by the Go Red for Women Venture Fund™ and Solas BioVentures

July 28, 2026
Aurenar Receives FDA Breakthrough Device Designation for Non-Invasive Neuromodulation Therapy Designed for the Reduction of Cerebral Vasospasm Following Brain Hemorrhage

June 30, 2026

Aurenar Closes Oversubscribed $5.7M Seed Round Led by the Go Red for Women Venture Fund™ and Solas BioVentures